MTRNR1基因m.1555A>G突变患者的感觉神经性听力损失
该观察性回顾性研究在西班牙坎塔布里亚的Marqués de Valdecilla大学医院耳鼻咽喉科开展,纳入疑似遗传性双侧感觉神经性听力损失患者及100例听力正常对照,发现20个家系共82人携带m.1555A>G突变,对照组均无此突变。患者听力损失程度从正常到极重度不等,有链霉素使用史者听力损失更明显,耳蜗植入者言语理解显著改善。作者建议对有听力损失家族史者行该突变基因检测,以在发现突变时避免使用氨基糖苷类。
要点
- m.1555A>G突变见于20个家系82人,100例听力正常对照均未检出。
- 听力损失程度从正常到极重度不等,以高频受累为主,有链霉素使用史者听力损失更明显。
- 未发现前庭功能异常或耳外临床表现;2例耳蜗植入者言语理解显著改善。
核心结论
- m.1555A>G突变患者常出现双侧对称性感觉神经性听力损失,以高频受累为主,链霉素使用可加重听力损失。
- 该突变不影响前庭功能。
- 听力损失严重程度变异、表型异质性及听力正常携带者的存在,可能提示存在环境与遗传的修饰因素。
- 耳蜗植入者言语可懂度反应良好。
- 作者建议对有听力损失家族史的患者行该突变基因检测,以在发现突变时避免使用氨基糖苷类。
研究设计与样本
- 观察性回顾性研究,在西班牙坎塔布里亚的Marqués de Valdecilla大学医院耳鼻咽喉科开展。
- 研究对象为疑似遗传性双侧感觉神经性听力损失患者,并设100例听力正常对照。
- 证据等级为4级,发表于Laryngoscope,2025年,135卷,901-907页。
主要发现
- m.1555A>G突变见于20个不同家系的82例个体,100例听力正常对照中均未发现该突变。
- 听力损失程度不等,从正常听力到极重度耳聋。
- 有链霉素使用史的患者听力损失显著更明显。
- 听力损失起病年龄从儿童期至成年期,多年间可进展或保持稳定。
- 未发现相关前庭功能改变或耳外其他临床表现。
临床怎么用
- 作者建议对有听力损失家族史的患者行该突变基因检测,以在发现突变时避免使用氨基糖苷类。
- 原文未据此给出其他临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mutations in the MTRNR1 gene of mitochondrial DNA are associated with non-syndromic hearing loss and increased susceptibility to aminoglycoside ototoxicity. The aim of our study was to determine the clinical characteristics of sensorineural hearing loss caused by the m.1555A>G mutation in MTRNR1. METHODS: An observational retrospective study of the m.1555A>G mutation was conducted in patients with suspected hereditary bilateral sensorineural hearing loss in the Department of Otolaryngology of the Marqués de Valdecilla University Hospital (Cantabria, Spain) and in 100 controls with normal hearing. RESULTS: The m.1555A>G mutation was found in 82 individuals from 20 different families and in none of the controls. Variable degrees of hearing loss were observed, ranging from normal hearing to profound deafness. Patients with a history of streptomycin administration exhibited significantly more pronounced hearing loss. The onset of hearing loss occurred from childhood to adulthood, with progression or stability over the years. No associated vestibular alterations or other clinical manifestations outside the ear were found. Two cochlear implant recipients showed significant improvement in speech comprehension. CONCLUSIONS: Patients with the m.1555A>G mutation in the MTRNR1 gene often develop bilateral, symmetric sensorineural hearing loss, predominantly affecting high frequencies, worsened by streptomycin administration. This mutation does not affect the vestibular function. The variability in the severity of hearing loss, the heterogeneity of phenotypic expression, and the presence of carrier individuals with normal hearing may indicate the existence of modifying factors, both environmental and genetic. Cochlear implantees showed a good response in terms of speech intelligibility. Genetic testing for this mutation is recommended in patients with a family history of hearing loss to prevent the use of aminoglycosides if the mutation is found. LEVEL OF EVIDENCE: 4 Laryngoscope, 135:901-907, 2025.
引用
- Gallo-Terán J, Salomón-Felechosa C, González-Aguado R, et al. Sensorineural Hearing Loss in Patients With the m.1555A>G Mutation in the MTRNR1 Gene. Laryngoscope. 2024. PMID: 39323315. doi:10.1002/lary.31796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。